

CFTR-PTEN-dependent mitochondrial metabolic dysfunction in *Pseudomonas aeruginosa* airway infection

Science Translational Medicine

11,

DOI: [10.1126/scitranslmed.aav4634](https://doi.org/10.1126/scitranslmed.aav4634)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Succinate links mitochondria to deadly bacteria in cystic fibrosis. <i>Annals of Translational Medicine</i> , 2019, 7, S263-S263.	0.7	2
2	Mitochondrial dysfunction in lung ageing and disease. <i>European Respiratory Review</i> , 2020, 29, 200165.	3.0	56
3	Targeting the Heme Oxygenase 1/Carbon Monoxide Pathway to Resolve Lung Hyper-Inflammation and Restore a Regulated Immune Response in Cystic Fibrosis. <i>Frontiers in Pharmacology</i> , 2020, 11, 1059.	1.6	22
4	Defective immunometabolism pathways in cystic fibrosis macrophages. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 664-672.	0.3	5
5	Airway immunometabolites fuel <i>Pseudomonas aeruginosa</i> infection. <i>Respiratory Research</i> , 2020, 21, 326.	1.4	13
6	Novel Antioxidant Therapy with the Immediate Precursor to Glutathione, γ -L-Glutamylcysteine (GGC), Ameliorates LPS-Induced Cellular Stress in In Vitro 3D-Differentiated Airway Model from Primary Cystic Fibrosis Human Bronchial Cells. <i>Antioxidants</i> , 2020, 9, 1204.	2.2	11
7	Comparative genomics in infectious disease. <i>Current Opinion in Microbiology</i> , 2020, 53, 61-70.	2.3	11
8	<i>Pseudomonas</i> Persists by Feeding off Itaconate. <i>Cell Metabolism</i> , 2020, 31, 1045-1047.	7.2	2
9	Single-Cell Transcriptional Archetypes of Airway Inflammation in Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1419-1429.	2.5	56
10	Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for <i>Pseudomonas aeruginosa</i> survival. <i>Scientific Reports</i> , 2020, 10, 10935.	1.6	25
11	Virulence attenuating combination therapy: a potential multi-target synergy approach to treat <i>Pseudomonas aeruginosa</i> infections in cystic fibrosis patients. <i>RSC Medicinal Chemistry</i> , 2020, 11, 358-369.	1.7	19
12	Pulmonary Pathogens Adapt to Immune Signaling Metabolites in the Airway. <i>Frontiers in Immunology</i> , 2020, 11, 385.	2.2	32
13	Evolutionary Genomics of Niche-Specific Adaptation to the Cystic Fibrosis Lung in <i>Pseudomonas aeruginosa</i> . <i>Molecular Biology and Evolution</i> , 2021, 38, 663-675.	3.5	18
14	Metabolic Modeling to Interrogate Microbial Disease: A Tale for Experimentalists. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 634479.	1.6	7
15	<i>Pseudomonas aeruginosa</i> : An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3128.	1.8	230
16	<i>Staphylococcus aureus</i> induces an itaconate-dominated immunometabolic response that drives biofilm formation. <i>Nature Communications</i> , 2021, 12, 1399.	5.8	72
17	Lack of CFTR alters the ferret pancreatic ductal epithelial secretome and cellular proteome: Implications for exocrine/endocrine signaling. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 172-180.	0.3	6
18	<i>Pseudomonas aeruginosa</i> Consumption of Airway Metabolites Promotes Lung Infection. <i>Pathogens</i> , 2021, 10, 957.	1.2	6

#	ARTICLE	IF	CITATIONS
19	The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects. <i>European Respiratory Review</i> , 2021, 30, 210055.	3.0	28
20	<i>Pseudomonas aeruginosa</i> Utilizes Host-Derived Itaconate to Redirect Its Metabolism to Promote Biofilm Formation. <i>Cell Metabolism</i> , 2020, 31, 1091-1106.e6.	7.2	109
22	Recent advances in primary immunodeficiency: from molecular diagnosis to treatment. <i>F1000Research</i> , 2020, 9, 194.	0.8	21
23	Control of host mitochondria by bacterial pathogens. <i>Trends in Microbiology</i> , 2022, 30, 452-465.	3.5	25
25	Immunometabolites Drive Bacterial Adaptation to the Airway. <i>Frontiers in Immunology</i> , 2021, 12, 790574.	2.2	11
26	Macrophages from gut-corrected CF mice express human CFTR and lack a pro-inflammatory phenotype. <i>Journal of Cystic Fibrosis</i> , 2021, , .	0.3	1
27	The role of itaconate in host defense and inflammation. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	135
28	Mitochondrial ACOD1/IRG1 in infection and sterile inflammation. <i>Journal of Intensive Medicine</i> , 2022, 2, 78-88.	0.8	16
29	Immunometabolic crosstalk during bacterial infection. <i>Nature Microbiology</i> , 2022, 7, 497-507.	5.9	45
30	CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis. <i>Cells</i> , 2022, 11, 1243.	1.8	14
31	Blood-brain barrierâ€“penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy. <i>Science Advances</i> , 2022, 8, eabm8011.	4.7	71
32	Overview of CF lung pathophysiology. <i>Current Opinion in Pharmacology</i> , 2022, 64, 102214.	1.7	10
33	Anti-Inflammatory Metabolites in the Pathogenesis of Bacterial Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	8
34	Mesenchymal stem cells in fibrotic diseasesâ€“the two sides of the same coin. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 268-287.	2.8	19
35	Moving beyond descriptive studies: harnessing metabolomics to elucidate the molecular mechanisms underpinning host-microbiome phenotypes. <i>Mucosal Immunology</i> , 2022, 15, 1071-1084.	2.7	9
36	Pulmonary neuroendocrine cells sense succinate to stimulate myoepithelial cell contraction. <i>Developmental Cell</i> , 2022, 57, 2221-2236.e5.	3.1	4
37	Development of liquid culture media mimicking the conditions of sinuses and lungs in cystic fibrosis and health. <i>F1000Research</i> , 0, 11, 1007.	0.8	2
38	<i>Pseudomonas aeruginosa</i> in the Cystic Fibrosis Lung. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 347-369.	0.8	6

#	ARTICLE	IF	CITATIONS
39	Cut microbiota-derived succinate aggravates acute lung injury after intestinal ischaemia/reperfusion in mice. <i>European Respiratory Journal</i> , 2023, 61, 2200840.	3.1	15
40	The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation. <i>Clinics in Chest Medicine</i> , 2022, 43, 647-665.	0.8	13
41	<i>Pseudomonas aeruginosa</i> . , 2023, , 884-889.e2.		1
42	Two for the price of one: itaconate and its derivatives as an anti-infective and anti-inflammatory immunometabolite. <i>Current Opinion in Immunology</i> , 2023, 80, 102268.	2.4	7
43	Development of liquid culture media mimicking the conditions of sinuses and lungs in cystic fibrosis and health. <i>F1000Research</i> , 0, 11, 1007.	0.8	6
44	PmiR senses 2-methylisocitrate levels to regulate bacterial virulence in <i>Pseudomonas aeruginosa</i> . <i>Science Advances</i> , 2022, 8, .	4.7	1
45	Metabolite interactions between host and microbiota during health and disease: Which feeds the other?. <i>Biomedicine and Pharmacotherapy</i> , 2023, 160, 114295.	2.5	19
46	<i>Staphylococcus aureus</i> stimulates neutrophil itaconate production that suppresses the oxidative burst. <i>Cell Reports</i> , 2023, 42, 112064.	2.9	23
47	Diagnosis and Management of Cystic Fibrosis Exacerbations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 225-241.	0.8	2
48	Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5010.	1.8	5
50	How <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i> Hijack the Host Immune Response in the Context of Cystic Fibrosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6609.	1.8	2
51	Control of mitochondrial functions by <i>Pseudomonas aeruginosa</i> in cystic fibrosis. <i>International Review of Cell and Molecular Biology</i> , 2023, , .	1.6	1